ARCHES: 5-year follow-up overall survival (OS) analysis of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC).
Armstrong A, Petrylak D, Shore N, Szmulewitz R, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Croitoru R, Wu R, Kalac M, Tang Y, Stenzl A, Azad A. ARCHES: 5-year follow-up overall survival (OS) analysis of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC). Journal Of Clinical Oncology 2025, 43: 5005-5005. DOI: 10.1200/jco.2025.43.16_suppl.5005.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyOverall survivalOS analysisRadiographic progression-free survivalHormone-sensitive prostate cancerLong-term follow-upGlobal phase 3Low-volume patientsOpen-label enzalutamideProgression-free survivalEfficacy of enzalutamideMedian Follow-UpOpen-label extensionKaplan-Meier methodLong-term efficacyStandard-of-careClinically relevant subgroupsCox regression modelsFollow-up dataARCH trialDocetaxel useMedian OSAndrogen deprivationDisease volume
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply